Lipopolysaccharide (LPS) is the eminent lipid component of the outer leaflet of the outer membrane of Gram-negative bacteria and the major initiator of innate immune response to bacterial infection. Below the critical micellar concentration (CMC), LPS is exclusively present as a monomer. Above this concentration, aggregates are formed. Increasing the concentration beyond the CMC leads to an increase in aggregate concentration, whereas the concentration of monomers remains constant or even decreases. The question how LPS activates immune cells and whether the aggregate or the monomer is the biologically active unit has been and still is controversial. To prepare clearly defined monomeric solutions, we utilized a dialysis set-up consisting of a donor and an acceptor chamber, separated by a dialysis diaphragm with a cut-off of 5 kDa, thus allowing only monomers to pass. Human mononuclear cells (MNCs) were then stimulated with equal concentrations of aggregates and monomers, respectively, of deep rough mutant LPS from Escherichia coli strain F515 (Re LPS) and TNF-α release was determined. In contrast to earlier and very recent work of others, we started with a preparation of aggregate-suspensions and pure monomer-solutions and show that monomers are significantly less active than aggregates in the absence and presence of serum proteins at identical concentrations. In our model, we propose that LPS aggregates are detected by membrane-associated LBP and intercalated into the cell membrane to bring LPS into close proximity to signaling proteins in the membrane, thus finally leading to cell activation. To support this model, we present data showing that LBP is indeed present in or at the cell membrane of human macrophages.
INTRODUCTION
Bacterial lipopolysaccharides (LPSs, endotoxin) are major constituents of the cell envelopes of Gram-negative bacteria. They consist of a lipid moiety, called lipid A, with 4-7 fatty acids and a sugar moiety, composed of a core oligosaccharide and an O-antigen with repeating sugar units. The release of LPS from bacterial cell walls into the host's blood circulation causes the activation of immune cells, resulting in the production of cytokines, nitric oxide, and tissue factors. Since the isolated lipid A moiety is already able to cause cell activation, it is called the 'endotoxic principle' of LPS. 1 Systemic production of pro-inflammatory mediators induced by LPS may be involved in the pathophysiology of a clinical syndrome named sepsis which leads to hypotension, fever, organ failure, and, in the worst case, to death. [2] [3] [4] The question of how bacterial endotoxins activate immune cells is not yet conclusively answered. There are many proteins -both membrane-bound and serum proteins -known to be involved in LPS-induced cell activation. One important membrane-bound protein is mCD14, a 55-kDa protein anchored to the membrane by a glycosylphosphatidylinositol anchor. 5 Due to its lack of a transmembrane domain, mCD14 cannot transfer a signal across the cell membrane. Instead, the probably most important function described for mCD14 is the binding and transfer of LPS or lipid A to other proteins, thus facilitating the delivery of LPS or lipid A to the host cell and enhancing cell activation. Toll-like receptor (TLR)4 was identified as a signal transducing co-receptor by molecular genetic analysis of the LPS hyporesponsive mouse strain C3H/HeJ 6 and the generation of a mouse strain with a targeted deletion of the gene for TLR4. 7 For functional signal transduction in response to LPS, TLR4 requires the presence of the secreted protein MD-2, which binds to the extracellular portion of TLR4. 8, 9 There is increasing evidence that, in addition to these proteins, several other proteins, such as a potassium channel, 10 heat shock proteins 70 and 90, 11 and others are engaged in building a complex receptor cluster.
Another important protein in this context is the LPSbinding protein (LBP) described as a 65-kDa soluble acute-phase serum protein produced by hepatocytes. Due to its positive charge, LBP binds to negatively charged molecules like LPS, and to anionic lipids such as phosphatidylserine or cardiolipin. 12 It enhances LPS-binding to the cell membrane, thus enhancing cell activation. 13 We showed previously that LBP not only mediates transport of LPS and phospholipids to cell membranes, but also intercalates itself into cell membranes. This membrane-bound LBP (mLBP) plays a role in cell activation most likely by binding LPS similar to the function of CD14. 14 In addition to its activating function, LBP also plays a role as a LPSneutralizing protein.
In order to understand the initial molecular steps in cell activation by LPS, we have to answer the question whether LPS activates immune cells in the aggregated or in the monomeric form. In an aqueous environment and above a lipid-specific concentration, the critical micellar concentration (CMC), amphiphilic molecules like lipid A and LPS form supramolecular aggregate structures. The aggregate structure strongly depends on the chemical structure and with that the molecular conformation of the aggregateforming molecules. Combined biophysical and immunological investigations into the role of the aggregate structure for biological activity have shown that only conicallyshaped molecules, which form cubic inverted aggregate structures, exhibit high endotoxic activity, whereas cylindrical molecules, forming lamellar aggregate structures, exhibit low or no endotoxic activity. 15 Thus, the shape of the aggregate-forming molecules, and with that the aggregate structure, correlate with the ability to activate host cells. This dependence has been shown for a variety of endotoxin as well as non-endotoxin structures. 16 The information on the nature of the biologically active unit of LPS is of utmost importance and extremely valuable for an understanding of the molecular mechanisms of cell activation. In this context it is interesting to note that pre-incubation of sLBP with LPS leads to a transition from cubic inverted to lamellar structures of the LPS-aggregates (own unpublished data). These lamellarized LBP-LPS complexes are neither able to intercalate into liposomal membranes nor do they induce cytokine production in immune cells. 14, 17 The commonly accepted model of cell activation proposes that LBP removes LPS monomers from these aggregates, transports them to mCD14 in a type of shuttle mechanism, from where it is passed onto TLR4 which then, together with MD-2, is responsible for transmembrane signaling and triggering of the intracellular signaling cascade, finally leading to cytokine production and release. 18 A recent paper from the group of Weiss suggests a vectorial transport along soluble proteins, with LBP binding to the LPS aggregate, obsonizing it for sCD14 which then monomerizes the aggregate. This sCD14-LPS monomer complex binds to sMD-2, and the resulting sMD-2-LPS monomer complex then binds to TLR4, leading to cell activation. 19 This model proposes that it is the monomer that first interacts with the host cell. This proposition is backed by the work of Takayama and colleagues who found that LPS is an order of 2.5 more active in stimulating a pro-B-cell line in a disaggregated state 20 and was more active in the LAL-assay than aggregated LPS. 21 In our model, we state that all proteins involved are membrane-bound or at least membrane-associated and that it is the aggregate that first interacts with the immune cells. This finding is supported by Shnyra et al. 22 who showed that aggregated LPS activated the LAL cascade to a higher degree and was lethal in galactosamine-sensitized mice in lower doses than monomeric LPS. We propose that mLBP binds LPS aggregates and possibly intercalates them into the cell membrane -as we could show for model membranes like phospholipid liposomes. 23 Intercalation of LPS into the membrane might bring the endotoxin into close proximity of the proteins of the signaling complex. Thus, in our model, the aggregate is the active unit of endotoxin which interacts with the cell membrane and membranebound proteins. Also, in our experiments the Limulus amoebocyte clotting assay was activated more potently by LPS in the aggregated form; 24 however, it is possible that different mechanisms take place at the same time.
Here we present new data showing that LBP is present on immune cells as a transmembrane or at least membrane-associated protein, which plays a role in LPS signaling even under serum-free conditions, and that LPS activates immune cells in the aggregated state.
MATERIALS AND METHODS
Deep rough mutant LPS from Escherichia coli strain F515 (Re LPS) was extracted by the phenol/chloroform/petroleum ether method. The LPS preparations were lyophilized and used in the natural salt form. Recombinant human LBP (456 amino acid holoprotein rLBP) was kindly provided by R. Dedrick (XOMA Corp., Berkeley, CA, USA). The monoclonal anti-LBP antibody BiG42 was obtained from Biometec (Greifswald, Germany). Phospholipids were purchased from Sigma Chemicals (Deisenhofen, Germany).
Monomers were prepared in a dialysis set-up consisting of a donor and an acceptor chamber separated by a diaphragm with a cut-off of 5 kDa, thus allowing only monomers to pass. The donor chamber was filled with Re LPS at a concentration of 10 -6 M which is well above the assumed CMC-value of Re LPS of approximately 10 -8 M 25 and the other chamber was filled with water . After 48 h, aqueous aliquots were taken from the acceptor and from the donor chamber, respectively, and assayed for LPS concentration and biological activity. The concentrations of the Re LPS aggregates on the donor and of the monomers on the acceptor side were determined via the quantitative measurement of (3-OH) 14:0 hydroxyl fatty acid by GC-MS. The concentrations in the donor and the acceptor chamber were 10 -6 M and about 4 x 10 -9 M, respectively. The incubation time of 48 h is sufficient for the equilibration of the monomer concentration in both chambers but is too short for disintegration of the aggregates in the donor chamber. Since the concentration of monomers on the acceptor side does not increase above the CMC, the formation of aggregates on the acceptor side is definitely excluded.
In experiments aimed at the determination of the cytokine-inducing capacity of LPS, human mononuclear cells were stimulated with LPS from the aliquots taken, and the subsequent TNF-α release was determined in the supernatant by sandwich ELISA as described. 26 For Western blotting, human blood derived macrophages (5 × 10 6 ) were lysed in 100 µl lysis buffer (2% SDS, 50 mM DTT, 62.5 mM Tris/HCl pH 6.8, 10% glycerol). After incubation at 100°C for 10 min, cell lysates were centrifuged at 10,000 g for 4 min. Lysates were then resolved by 9% SDS-PAGE and electrotransferred to nitrocellulose. Western blotting was performed with the primary antibody anti-LBP (Biometec), followed by anti-mouse horseradish peroxidase (HRP)-conjugated IgG (Jackson ImmunoResearch Laboratories). Blots were developed with ECL.
RESULTS AND DISCUSSION

Re LPS displays its biological activity only as aggregates, but not as monomers
In order to elucidate whether the monomer or the aggregate is the biologically active unit of endotoxin, we utilized a dialysis system that allows the separation of monomers from aggregate suspensions.
Stimulation of human mononuclear cells with aggregated and monomeric samples of Re LPS (Fig. 1) showed that aggregate suspensions have significantly higher biological activity than monomer solutions of identical concentration. Data are presented in relative units to stress differences between aggregates and monomers rather than to highlight donor variability and their differences in ability to induce TNF-α under serum-free or serum-containing conditions. Using cells from various donors, in each case comparable results could be obtained under serum-free culture conditions, under serum-free conditions in the presence of the LPS-binding protein LBP, and in the presence of human AB serum.
These data clearly indicate that for the stimulation of human MNCs in the presence as well as in the absence of serum the biologically active unit of LPS is the aggregate and not the monomer. This fact is equally true for the 'endotoxic principle' of LPS, lipid A, and the LPS with the complete core-region, Ra LPS. 24, 27 These findings do, however, not exclude a role of monomeric protein-endotoxin complexes in cell activation under different starting conditions.
LBP is present on immune cells under serum-free conditions
We showed earlier that LBP intercalates into model membranes such as liposomes or reconstituted planar membranes and assumes a transmembrane configuration. 14 Further, we demonstrated that binding of antibodies to LBP on the cell surface inhibits LPS-induced cell activation. 12 Here, we present new data showing that LBP is also present on human immune cells. Whole cell Endotoxin: physical requirements for cell activation 301 Fig. 1 . Endotoxin aggregates are more potent stimulators of immune cells than monomers. TNF-α production from MNCs after stimulation with LPS aggregates (dark boxes) and monomers (light boxes) in similar concentrations (10 -9 M). TNF-α production of aggregates was set to 100% and TNF-α production of monomers was normalized to the respective aggregate value and shown as mean ± SD. LBP, 100 ng/ml; human serum, 4%.
lysates of human macrophages were produced to elucidate whether LBP is present on the cytoplasmic membrane of immune cells (Fig. 2) . In lane A, lysates of human macrophages, which were washed several times to remove soluble LBP, were applied to the gel. In lane B, the macrophages were incubated with LBP-containing serum before cell lysis. In lane C, recombinant human LBP was applied as a control. These data show that LBP could be detected on the cell lysates even when human macrophages were washed in serum-free medium several times.
The dual role of LBP
As already shown, LBP is involved in the LPS-induced cytokine release of MNCs under serum-free conditions. 14 Binding of LBP to, and intercalation into, reconstituted lipid membranes is enhanced by negatively charged lipids. Intercalated LBP can then mediate the intercalation of LPS into the membranes. In contrast, prior complexation of LBP and LPS causes inhibition of binding of these complexes to the membrane due to different binding between LBP and LPS and LBP and phospholipids, respectively. Furthermore, pre-incubation with LBP leads to lamellarization of LPS aggregates (our unpublished data). This results in neutralization of LPS activity and, with that, in a reduction of TNF-α production by MNCs. We propose that LBP is located in strong association to the cytoplasmic membrane of MNCs -as has been shown for BPI 28 -or even intercalated into it, and that interaction of LPS aggregates with membrane-associated LBP may be an important step in LBP-mediated activation of macrophages and MNCs by LPS, whereas binding of LPS aggregates to soluble LBP provokes neutralization of LPS. In in vitro (in the presence of serum) and in particular in in vivo experiments, this clear distinction between the two roles of LBP can not be elaborated, because the effects are concentration-dependent, and a variety of further proteins and other serum constituents (e.g. soluble CD14, 29 BPI, 30 CAP18, 31 and lipoproteins 32 ) enhance or suppress LPS-induced activation of MNCs. 
